14, rue de la Colombière
44 articles with Mymetics Corporation
Mymetics to Advance Preclinical Studies for Virosome-based COVID-19 Vaccine through Innosuisse Grant
Mymetics SA, a subsidiary of Mymetics Corporation, a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, and Insel Gruppe AG, of which the Inselspital, Bern University Hospital, are part of, announced that they have been awarded a grant from the Swiss Innovation Agency.
Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine.
Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine
Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine.
Mymetics Receives Support for Virosome-based Covid-19 Vaccine Development from European Vaccine Infrastructure Project (Transvac2)
Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that its subsidiary, Mymetics SA, has received the confirmation to receive access to the European vaccine infrastructure TRANSVAC2
Mymetics and Baylor College of Medicine start Research Collaboration for Virosome-based Covid-19 Vaccines
Mymetics Corporation announced that its subsidiary, Mymetics BV, has signed a Research Collaboration Agreement with Baylor College of Medicine and Texas Children's Center for Vaccine Development for evaluating their rationally designed recombinant protein-based SARS-CoV and SARS-CoV-2 antigens and combining them with Mymetics' virosomes for the development of a safe and effective Covid-19 vaccine.
Funding to prepare Mymetics' cold chain independent needle free mucosal virosome HIV vaccine candidate for clinical trials
Poster presentation showing pre-clinical in vivo results investigating antibody titer strength, duration and functionality of malaria transmission blocking Pfs230 virosome-based vaccine compared to a benchmark formulation
Mymetics Corporation announced today that Mymetics BV, the Dutch subsidiary of Mymetics Corporation, has entered into a research collaboration project with eTheRNA immunotherapies NV, a clinical stage biotech company developing novel mRNA cancer immunotherapies.
MYMETICS Corporation-Led Consortium Awarded €8.4 Million For Development Of Thermo Stable And Cold-Chain Independent Vaccines
MYMETICS Corporation Announces New Collaboration To Advance The Development Of An Innovative Malaria Vaccine Candidate
MYMETICS Corporation’ Promising HIV Vaccine Candidate Obtains Funding To Begin Study At Texas Biomedical Research Institute
MYMETICS Corporation Ropes in Dendreon Corporation, KPCB Vets as New CEO and Board Members to Restart Vaccine Developer